CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaShannon L. Maude, Stephan A. Grupp|Blood|2015Cited by 718
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Marco Ruella, Yong Gu Lee et al.|Cancer Discovery|2020Cited by 297
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemiaKaren L. Bride, David T. Teachey, Tiffaney L. Vincent et al.|Blood|2018Cited by 226
FOXO1 is a master regulator of memory programming in CAR T cellsAlexander Doan, Evan W. Weber, Katherine P. Mueller et al.|Nature|2024Cited by 189
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemiaSarah K. Tasian, Stephan A. Grupp|Blood|2016Cited by 163